Skin Cancer Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Skin Cancer Diagnostics and Therapeutics Market is segmented by Cancer Type (Melanoma, and Non-melanoma), Type (Diagnosis and Therapeutics), and Geography.

Market Snapshot

skin cancer diagnostics and therapeutics market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Certain factors driving the market growth include increasing incidence of skin cancer, extensive R&D pipelines, and rising awareness about skin cancer. Skin cancer is the most common form of cancer. Even though most types of skin cancers are preventable, its incidence is increasing. People can recognize changes in their skin during the early stages of the disease. The risk factors include sunlight, sunlamps and tanning booths, certain medical conditions, or medicines. The UV radiation changes the genetic material (DNA) in cells and is, therefore, the main cause of skin cancer. According to the American Cancer Society, exposure to the sun is the most preventable risk factor for all skin cancers. The rate of new melanoma cases among both men and women has been increasing at 1.7% and 1.4% per year respectively, as per the data of the Federal Centers for Disease Control and Prevention (CDC). Thus, the increasing prevalence of skin cancer is augmenting the growth of the market studied.

However, a common side effect of radiation therapy is skin irritation in the area of the body that is being treated. The skin reaction can range from mild redness and dryness (similar to a sunburn) to severe peeling (desquamation) of the skin in some patients. The majority of skin reactions to radiation therapy go away a few weeks after the treatment is completed. In some cases, the treated skin will remain slightly darker than it was before and may continue to be more sensitive to sun exposure. About two to three weeks after first radiation treatment, redness is noticed and irritation is similar to a sunburn. The skin may be itchy, dry, red, or sore. There are also long-term side effects, like changes in skin color, lung problems, and others, which act as major restraints for the growth of the market studied.

Scope of the Report

Ultraviolet radiation is a primary carcinogen that results in UV induced mutations, loss of activity in tumor suppressor genes, and the overexpression of oncogenes in keratinocytes, thus boosting the development of skin malignancies. The skin cancer diagnostics and therapeutics market comprise of various diagnostics and therapies related to skin cancer.

By Cancer Type
Melanoma
Non-melanoma
By Type
Diagnosis
Dermatoscopy
Biopsy
Genetic Tests
Others
Therapeutics
Chemotherapy
Immunotherapy
Targeted Therapy
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Non-melanoma is Expected to Hold a Significant Market Share in the Cancer Type

According to the ASCO (American Society of Clinical Oncology), it is estimated that more than 3 million people in the United States are diagnosed with non-melanoma skin cancer each year. Basal cell carcinoma is far more common than squamous cell carcinoma. About 80% of non-melanoma skin cancer is basal cell carcinoma. Similarly, the CCS (Canadian Cancer Society) states that non-melanoma skin cancer is the most common cancer diagnosed among Canadians. It makes up at least 40% of all new cancer cases in Canada.

Furthermore, it has been stated by the National Institute of Health that there were around 948 deaths observed during the year 2017 due to non-melanoma skin cancer in Japan. Similarly, Australia is also facing the burden of non-melanoma skin cancer deaths. Cancer Council has stated that around 679 deaths were noted during the year 2016-2027 due to this cancer in Australia.

Furthermore, the rising burden of melanoma skin cancer is also expected to drive the market in the forecast period.

Skin Cancer Diagnostics and Therapeutics Market 3.png

North America Dominates the Market and expected to do Same in the Forecast Period

North America is expected to dominate the market in the forecast period. As per the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma, the deadliest kind of skin cancer, are caused by exposure to ultraviolet (UV) light. It is estimated that approximately 9,500 people in the United States are diagnosed with skin cancer every day. Thus, the increasing incidences of skin cancer in the region is a major factor driving the growth of the market studied. Additionally, the recent advancements of skin cancer therapy, including photodynamic therapy (PDT), have been widely used in treating non-melanoma skin malignancies, thus boosting the growth of the market studied during the forecast period.

Skin Cancer Diagnostics and Therapeutics Market 2

Competitive Landscape

The global skin cancer diagnostics and therapeutics market is highly competitive and consists of a number of major players. Companies, like Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., among others, hold the substantial market share in the skin cancer therapeutics market.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Skin Cancer

      2. 4.2.2 Rising Awareness About Skin Cancer

      3. 4.2.3 Extensive R&D Pipelines

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost Associated with Therapy

      2. 4.3.2 Stringent Regulatory Framework

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Melanoma

      2. 5.1.2 Non-melanoma

    2. 5.2 By Type

      1. 5.2.1 Diagnosis

        1. 5.2.1.1 Dermatoscopy

        2. 5.2.1.2 Biopsy

        3. 5.2.1.3 Genetic Tests

        4. 5.2.1.4 Others

      2. 5.2.2 Therapeutics

        1. 5.2.2.1 Chemotherapy

        2. 5.2.2.2 Immunotherapy

        3. 5.2.2.3 Targeted Therapy

        4. 5.2.2.4 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Amgen, Inc.

      3. 6.1.3 Pfizer Inc.

      4. 6.1.4 Bristol-Myers Squibb Company

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Sanofi S.A.

      7. 6.1.7 Merck & Co., Inc.

      8. 6.1.8 Novartis AG

      9. 6.1.9 Qiagen NV

      10. 6.1.10 Sun Pharmaceutical Industries Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Skin Cancer Diagnostics and Therapeutics Market market is studied from 2018 - 2026.

The Skin Cancer Diagnostics and Therapeutics Market is growing at a CAGR of 10% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Sun Pharmaceutical Industries Ltd., Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd. are the major companies operating in Skin Cancer Diagnostics and Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!